NDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OPTIRAY 320 (ioversol) by Guerbet is x-ray contrast activity [moa]. Approved for renal impairment, coronary artery disease, diabetes mellitus and 1 more indications. First approved in 1988.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 320 (ioversol) is a radiographic contrast agent administered by injection to enhance X-ray imaging in patients with cardiovascular and renal conditions. It works through X-ray contrast activity, enabling visualization of coronary arteries and renal structures in diagnostic procedures. The drug is indicated for patients with renal impairment, coronary artery disease, diabetes mellitus, and hypothyroidism undergoing contrast-enhanced imaging.
LOE Approaching
As an established diagnostic agent approaching loss of exclusivity with moderate competitive pressure (30%), teams should expect focus on cost management and market defense strategies rather than growth initiatives.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (4)
Worked on OPTIRAY 320 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.